Publications known to the writing group were supplemented with additional papers identified
by searching Medline/PubMed for publications in the last 12 years using keywords …

Haemophilia is a recessively inherited coagulation disorder, in which an X-chromosome
mutation causes a deficiency of either coagulation factor VIII (FVIII) in haemophilia A, or …

Hemophilia A is a worldwide disorder of coagulation system. It is a male disorder, yet
females with hemophilia are rarely seen in communities with high rate of consanguineous …

The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which
have been bioengineered to achieve prolonged activity, brings with it the need to consider …

Hemophilia A is the inherited bleeding disorder that results from mutation of blood
coagulation factor VIII (fVIII). Described here is the generation of a regulated expression …

Factor VIII (FVIII) may be measured by three different methodologies in the clinical
laboratory: one‐stage clotting assay, two‐stage clotting assay, and chromogenic assay …

Introduction Acquired haemophilia A (AHA) is a rare, often severe, auto‐immune bleeding
disorder caused by the development of inhibitory antibodies (inhibitors) to factor VIII (FVIII) …

The treatment of a patient with a factor VIII (FVIII) deficiency can be complicated. The
mainstay of therapy is factor replacement. Replacement therapy can be given …

Severity assessment of patients with haemophilia A (HA) is traditionally based on FVIII
activity (FVIII: C). Clinical phenotype of HA patients often differs between individuals with the …

INTRODUCTION: The quantitation of factor (F) VIII by activity-based assays is influenced by
the method, procedure, the quality and properties of reagents used and concentrations of …